Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Shanghai
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Tasly Pharmaceutical Group Co Ltd

+ Add to Watchlist

600535:CH

47.880 CNY 0.780 1.66%

As of 22:15:12 ET on 05/04/2015.

Snapshot for Tasly Pharmaceutical Group Co Ltd (600535)

Open: 47.170 Day's Range: 47.000 - 48.190 Volume: 4,724,112
Previous Close: 47.100 52wk Range: 35.830 - 51.430 1-Yr Rtn: +30.09%

Stock Chart for 600535

No chart data available.
  • 600535:CH 47.880
  • 1D
  • 1M
  • 1Y
47.100
Interactive 600535 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 600535

Current P/E Ratio (ttm) 34.4964
Estimated P/E(12/2015) 28.8149
Relative P/E vs. SHASHR 1.5794
Earnings Per Share (CNY) (ttm) 1.3674
Est. EPS (CNY) (12/2015) 1.6370
Est. PEG Ratio -
Market Cap (M CNY) 50,966.05
Shares Outstanding (M) 1,080.48
30 Day Average Volume 14,728,650
Price/Book (mrq) 7.6791
Price/Sale (ttm) 4.0040
Dividend Indicated Gross Yield 0.83%
Cash Dividend (CNY) 0.3900
Dividend Ex-Date
5 Year Dividend Growth 11.84%
Next Earnings Announcement 08/10/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 600535

  • Revenue
  • Net Income (M/CNY)
  • Profit Margin (%)

Company Profile & Key Executives for 600535

Tasly Pharmaceutical Group Co researches, produces, and sells Chinese medicines which are mainly derived from the root of red-rooted salvia. The Company's products focus on the treatment of cardiovascular and brain blood vessel diseases.

Kaijing YanChairmanZhu YonghongVice Chairman/President
Wang RuihuaVP/ControllerLiu JunfengVP/Secretary
More Company Profile & Key Executives for 600535

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil